BLSM Stock Forecast & Price Target

BlossomHill Therapeutics is attractive because its lead asset, BH-30643, is already generating differentiated Phase 1/2 evidence in EGFR-mutant NSCLC, including a 53% response rate in 34 evaluable C797S+ patients and 78% ORR in 27 TKI-naive classical EGFR+ patients, while maintaining a safety profile that appears manageable relative to wild-type EGFR inhibition. Its balance sheet also supports execution, with $95.4M in cash at 2Q26 plus $168.3M of IPO proceeds, implying runway into 2Q28 and reducing financing risk ahead of anticipated clinical readouts and a potential pivotal Phase 2 launch in 1Q27. Beyond the lead program, BH-30236 is showing early anti-leukemic activity in R/R AML and HR-MDS, and BH-501284 adds longer-dated upside in KRAS, reinforcing a diversified, high-upside precision-oncology platform led by a proven oncology drug-discovery team.

BlossomHill Therapeutics is viewed negatively because it has never been profitable and may not reach profitability until the early2030s, with that outlook hinging on FDA approval of BH-30643 while the company may still need to raise additional capital to fund operations. Its lead asset also faces commercialization risk from a crowded EGFR landscape, where osimertinib resistance is common and newer competitors like Zegfrovy and Rybrevant raise efficacy, safety, and availability questions, while BH-30643 itself has shown treatment-related Grade ≥3 ALT/AST elevations and other hepatic toxicity concerns. Beyond BH-30643, the broader pipeline remains unproven, as BH-30236 and BH-501284 are still earlier-stage programs, leaving limited evidence that BlossomHill can generate durable clinical or financial traction in the near term.